industry

Bharat Biotech’s 'Covaxin' gets SEC nod for phase 2-3 clinical trials on 2 to 18 year-olds


Subject Expert Committee (SEC) gave nod to Bharat Biotech’s ‘Covaxin’ for phase 2 and 3 human clinical trials on 2 to 18 years. In the ongoing vaccination drive in India, the ‘Covaxin’ is being used in adults. ‘Covaxin’ is one of the two vaccines being manufactured in India currently and has been developed by Bharat Biotech.



READ SOURCE

Read More   Regulators can’t rejig bid-based tariffs: Aptel

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.